How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

145,554 results for

Hypertension

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Hypertension Canada's 2018 guidelines for the management of hypertension in pregnancy

Hypertension Canada's 2018 guidelines for the management of hypertension in pregnancy Guidelines Hypertension Canada’s 2018 Guidelines for the Management of Hypertension in Pregnancy Sonia Butalia, BSc, MD, MSc, a,b,c Francois Audibert, MD, MSc, d Anne-Marie Côt e, MD, MHSc, e Tabassum Firoz, MD, MSc, f Alexander G. Logan, MD, g Laura A. Magee, MD, MSc, h,i William Mundle, MD, j Evelyne Rey, MD, MSc, k Doreen M. Rabi, MD, MSc, a,b,c Stella S. Daskalopoulou, MD, PhD, l and Kara A. Nerenberg, MD (...) , MSc; b,c,m for Hypertension Canada a Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; b Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada; c O’Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada; d Department of Obstetrics and Gynecology, CHUSainteJustine,Universit e deMontr eal,Montr eal,Qu ebec,Canada; e Universit e deSherbrooke,Sherbrooke,Quebec,Canada; f

2018 CPG Infobase

2. Diagnosis & Assessment of Hypertension - Renovascular Hypertension

Diagnosis & Assessment of Hypertension - Renovascular Hypertension VII. Assessment for Renovascular Hypertension | Hypertension Canada Guidelines Subgroup Members: Marcel Ruzicka, MD PhD; Sheldon W. Tobe, MD MScCH; Ramesh Prasad, MBBS MSc MA PhD; Michel Vallée, MD PhD; Cedric Edwards, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C. Harris, MD MHSc; Kerry (...) McBrien, MD MPH; Sonia Butalia, BSc MD MSc; Meranda Nakhla, MD MSc Co-Chairs: Doreen M. Rabi, MD MSc, Stella S. Daskalopoulou, MD MSc DIC PhD This information is based on the Hypertension Canada guidelines published in Nerenberg, Kara A. et al. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. . Guidelines Patients presenting with ≥ 2 of the following clinical clues listed below, suggesting renovascular hypertension

2018 Hypertension Canada

3. Diagnosis & Assessment of Hypertension - Endocrine Hypertension

Diagnosis & Assessment of Hypertension - Endocrine Hypertension VIII. Assessment For Endocrine Hypertension | Hypertension Canada Guidelines Subgroup Members: Ally P.H. Prebtani, MD; Gregory Kline, MD, Ernesto L. Schiffrin, MD PhD; Andrew Don-Wauchope, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C. Harris, MD MHSc; Kerry McBrien, MD MPH; Sonia Butalia (...) , BSc MD MSc; Meranda Nakhla, MD MSc Co-Chairs: Doreen M. Rabi, MD MSc, Stella S. Daskalopoulou, MD MSc DIC PhD This information is based on the Hypertension Canada guidelines published in Nerenberg, Kara A. et al. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. . Guidelines Hyperaldosteronism: screening and diagnosis Screening for hyperaldosteronism should be considered in hypertensive patients

2018 Hypertension Canada

4. Hypertension Canada's 2016 Canadian Hypertension Education Program guidelines for pharmacists: an update

Hypertension Canada's 2016 Canadian Hypertension Education Program guidelines for pharmacists: an update CPJ/RPC • november / december 2016 • VOL 149, NO 6 337 © The Author(s) 2016 DOI: 10.1177/1715163516671747 Practice guidelines Peer-reviewed Practice guidelines * Peer-reviewed 671747 CPHXXX10.1177/1715163516671747C P J / R P CC P J / R P C research-article2016 Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for pharmacists: An update Yazid N. Al Hamarneh, BSc (...) (Pharm), PhD; Sherilyn K. D. Houle, BSP , PhD; Raj Padwal, MD, MSc; Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP , FACC The Canadian Hypertension Education Program (CHEP) has been preparing and pub- lishing guidelines for diagnosis and management of hypertension since 1999. 1 The 2016 guide- lines, 2 released earlier this year, mark the 18th yearly production and update of evidence to date in the area of hypertension. Those guidelines, among other Hypertension Canada activities, can be considered

2016 CPG Infobase

5. Hypertension in pregnancy: diagnosis and management

Hypertension in pregnancy: diagnosis and management Hypertension in pregnancy: diagnosis Hypertension in pregnancy: diagnosis and management and management NICE guideline Published: 25 June 2019 www.nice.org.uk/guidance/ng133 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Hypertension in pregnancy: diagnosis and management (NG133) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 54Contents Contents Overview 5 Who

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

6. Hypertension in adults: diagnosis and management

Hypertension in adults: diagnosis and management Hypertension in adults: diagnosis and Hypertension in adults: diagnosis and management management NICE guideline Published: 28 August 2019 www.nice.org.uk/guidance/ng136 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Hypertension in adults: diagnosis and management (NG136) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 40Contents Contents Overview 4 Who

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

7. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT

Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find

2019 NIHR HTA programme

8. Phosphodiesterase 5 inhibitors for pulmonary hypertension. (PubMed)

Phosphodiesterase 5 inhibitors for pulmonary hypertension. Pulmonary hypertension (PH) comprises a group of complex and heterogenous conditions, characterised by elevated pulmonary artery pressure, and which left untreated leads to right-heart failure and death. PH includes World Health Organisation (WHO) Group 1 pulmonary arterial hypertension (PAH); Group 2 consists of PH due to left-heart disease (PH-LHD); Group 3 comprises PH as a result of lung diseases or hypoxia, or both; Group 4 (...) includes PH due to chronic thromboembolic occlusion of pulmonary vasculature (CTEPH), and Group 5 consists of cases of PH due to unclear and/or multifactorial mechanisms including haematological, systemic, or metabolic disorders. Phosphodiesterase type 5 (PDE5) inhibitors increase vasodilation and inhibit proliferation.To determine the efficacy of PDE5 inhibitors for pulmonary hypertension in adults and children.We performed searches of CENTRAL, MEDLINE, Embase, CINAHL, and Web of Science up to 26

2019 Cochrane

9. Assessment of hypertension

Assessment of hypertension Assessment of hypertension - Differential diagnosis of symptoms | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Assessment of hypertension Last reviewed: February 2019 Last updated: February 2019 Summary Hypertension is a common disorder that affects a large proportion of the community. It is usually asymptomatic and is detected on routine examination or after the occurrence of a complication such as a heart attack or stroke (...) . Lip GY. Hypertension, platelets, and the endothelium: the "thrombotic paradox" of hypertension (or "Birmingham paradox") revisited. Hypertension. 2003 Feb;41(2):199-200. http://hyper.ahajournals.org/cgi/content/full/41/2/199 http://www.ncbi.nlm.nih.gov/pubmed/12574081?tool=bestpractice.com Hypertension has been defined in joint guidelines by American learned bodies (American College of Cardiology [ACC] and American Heart Association [AHA] among others) Whelton PK, Carey RM, Aronow WS, et al. 2017

2019 BMJ Best Practice

10. Guided imagery for treating hypertension in pregnancy. (PubMed)

Guided imagery for treating hypertension in pregnancy. Hypertension (high blood pressure) in pregnancy carries a high risk of maternal morbidity and mortality. Although antihypertensive drugs are commonly used, they have adverse effects on mothers and fetuses. Guided imagery is a non-pharmacological technique that has the potential to lower blood pressure among pregnant women with hypertension. Guided imagery is a mind-body therapy that involves the visualisation of various mental images (...) to facilitate relaxation and reduction in blood pressure.To determine the effect of guided imagery as a non-pharmacological treatment of hypertension in pregnancy and its influence on perinatal outcomes.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register, and two trials registers (October 2018). We also searched relevant conference proceedings and journals, and scanned the reference lists of retrieved studies.We included randomised controlled trials (RCTs). We would have included RCTs

2019 Cochrane

11. Prostacyclin for pulmonary arterial hypertension. (PubMed)

Prostacyclin for pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is characterised by pulmonary vascular changes, leads to elevated pulmonary artery pressures, dyspnoea, a reduction in exercise tolerance, right heart failure, and ultimately death.Prostacyclin analogue drugs mimic endogenous prostacyclin which leads to vasodilation, inhibition of platelet aggregation, and reversal of vascular remodelling. Prostacyclin's short half-life theoretically enhances selectivity

2019 Cochrane

12. Pharmacotherapy for hypertension in adults 60 years or older. (PubMed)

Pharmacotherapy for hypertension in adults 60 years or older. This is the second substantive update of this review. It was originally published in 1998 and was previously updated in 2009. Elevated blood pressure (known as 'hypertension') increases with age - most rapidly over age 60. Systolic hypertension is more strongly associated with cardiovascular disease than is diastolic hypertension, and it occurs more commonly in older people. It is important to know the benefits and harms (...) of antihypertensive treatment for hypertension in this age group, as well as separately for people 60 to 79 years old and people 80 years or older.Primary objective• To quantify the effects of antihypertensive drug treatment as compared with placebo or no treatment on all-cause mortality in people 60 years and older with mild to moderate systolic or diastolic hypertensionSecondary objectives• To quantify the effects of antihypertensive drug treatment as compared with placebo or no treatment on cardiovascular

2019 Cochrane

13. Prostanoids and their analogues for the treatment of pulmonary hypertension in neonates. (PubMed)

Prostanoids and their analogues for the treatment of pulmonary hypertension in neonates. Persistent pulmonary hypertension of the newborn (PPHN) is a disease entity that describes a physiology in which there is persistence of increased pulmonary arterial pressure. PPHN is characterised by failure to adapt to a functional postnatal circulation with a fall in pulmonary vascular resistance. PPHN is responsible for impairment in oxygenation and significant neonatal mortality and morbidity

2019 Cochrane

14. Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy. (PubMed)

Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy. The hypertensive disorders of pregnancy include pre-eclampsia, gestational hypertension, chronic hypertension, and undefined hypertension. Pre-eclampsia is considerably more prevalent in low-income than in high-income countries. One possible explanation for this discrepancy is dietary differences, particularly calcium deficiency. Calcium supplementation in the second half (...) to be inadequate. This is an update of a review first published in 2017.To determine the effect of calcium supplementation, given before or early in pregnancy and for at least the first half of pregnancy, on pre-eclampsia and other hypertensive disorders, maternal morbidity and mortality, and fetal and neonatal outcomes.We searched the Cochrane Pregnancy and Childbirth Trials Register (31 July 2018), PubMed (13 July 2018), ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP; 31

2019 Cochrane

15. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Current pulmonary hypertension treatment guidelines recommend use of a risk stratification model encompassing a range of parameters, allowing patients to be categorised as low, intermediate or high risk. Three abbreviated versions of this risk stratification model were previously evaluated in patients with pulmonary arterial hypertension (PAH) in the French, Swedish and COMPERA registries. Our (...) objective was to investigate the three abbreviated risk stratification methods for patients with mostly prevalent PAH and chronic thromboembolic pulmonary hypertension (CTEPH), in patients from the PATENT-1/2 and CHEST-1/2 studies of riociguat.Risk was assessed at baseline and at follow-up in PATENT-1 and CHEST-1. Survival and clinical worsening-free survival were assessed in patients in each risk group/strata.With all three methods, riociguat improved risk group/strata in patients with PAH after 12

2019 EvidenceUpdates

16. Hypertension

Hypertension Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

17. Latanoprostene bunod (Vyzulta) - for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

Latanoprostene bunod (Vyzulta) - for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product

2019 Health Canada - Drug and Health Product Register

18. Evaluation and Treatment of Asymptomatic Hypertension

Evaluation and Treatment of Asymptomatic Hypertension Evaluation and Treatment of Asymptomatic Hypertension | Emergency Medicine | Washington University in St. Louis Open Menu Back Close Menu Search for: Loading... Welcome Our Team Sections Education Alumni Research ECRC Journal Club Events Jermyn Lectures Open Search Vignette You are working an evening shift in The Deuce when your next patient is roomed—a 53-year-old African American woman whose chief complaint is elevated blood pressure. She (...) for articles publised between 1/1/2010 to 3/13/2019 (i.e. since the previous journal club) using the terms (hypertens* OR elevated blood pressure) AND “emergency department”. . This strategy yielded articles from which the four most relevant articles were chosen. Articles Article 1: Article 2: . Article 3: . Article 4: Bottom Line Hypertension, which , represents not only a significant public health burden, but also places a significant burden on emergency departments. In the US, 2006 and 2013, rising from

2019 Washington University Emergency Medicine Journal Club

19. Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Natriuretic Peptide Testing for Pulmonary Arterial Hypertension: Clinical (...) Effectiveness, Cost-Effectiveness, and Guidelines Last updated: July 24, 2019 Project Number: RB1358-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of natriuretic peptide testing for prognosis or guiding therapy for pulmonary arterial hypertension? What is the cost-effectiveness of natriuretic peptide testing for prognosis or guiding therapy for pulmonary arterial hypertension? What are the guidelines

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

20. Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety

Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety | CADTH.ca Find the information you need Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety Nonsteroidal Anti-Inflammatory Drugs and Hypertension: Safety Last updated: January 24, 2019 Project Number: RB1300-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the evidence associated with the development (...) of hypertension upon the use of nonsteroidal anti-inflammatory drugs to treat acute pain? Key Message No relevant literature was identified regarding the evidence associated with the development of hypertension upon the use of nonsteroidal anti-inflammatory drugs to treat acute pain. Files Rapid Response Summary of Abstracts Published : January 24, 2019 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>